Endocrine Pharmacology Practice Questions

Q: What conditions is Metformin primarily used to treat?

Both Type 2 Diabetes and Polycystic Ovary Syndrome (PCOS). ***Both Type 2 Diabetes and Polycystic Ovary Syndrome (PCOS)*** - **Metformin** is a first-line treatment for **Type 2 Diabetes** due to its ability to decrease hepatic glucose production and improve insulin sensitivity [1], [2]. - It is also commonly used off-label for **PCOS** to improve insulin resistance, ovulation, and reduce androgen levels. *Only Type 2 Diabetes* - While Metformin is a cornerstone for **Type 2 Diabetes** treatment, stating "only" is incorrect as it has other significant therapeutic uses [2]. - Its benefits extend beyond diabetes management, particularly in conditions involving **insulin resistance**. *Only Polycystic Ovary Syndrome (PCOS)* - Metformin is used in **PCOS**, but it is not the sole condition it treats, and its primary indication remains **Type 2 Diabetes** [2]. - This option incorrectly limits its application to just one condition, overlooking its major role in diabetes. *Pregnancy Induced Hypertension* - **Metformin** is not indicated for the treatment of **pregnancy-induced hypertension** (gestational hypertension). - Treatment for pregnancy-induced hypertension typically involves medications like **labetalol**, **methyldopa**, or **nifedipine**, with delivery being the definitive management for severe cases.

Q: Which medication increases insulin secretion from beta cells?

Repaglinide. ***Repaglinide*** - This medication is a **meglitinide analog** that stimulates **insulin release** from pancreatic beta cells by closing ATP-sensitive potassium channels. - Its fast onset and short duration of action make it particularly useful for controlling **postprandial glucose** excursions. *Metformin* - This medication primarily works by **decreasing hepatic glucose production** and improving insulin sensitivity in peripheral tissues. - It does **not directly stimulate insulin secretion** from beta cells; thus, it carries a lower risk of hypoglycemia compared to sulfonylureas or meglitinides. *Pramlintide* - This is an **amylin analog** that works by slowing gastric emptying, suppressing postprandial glucagon secretion, and increasing satiety. - It is an **injectable medication** used as an adjunct to insulin therapy and does not directly enhance insulin secretion from beta cells. *Pioglitazone* - This drug is a **thiazolidinedione** that improves insulin sensitivity in target tissues (e.g., muscle, fat, liver) by activating **peroxisome proliferator-activated receptor-gamma (PPAR-γ)**. - While it improves the body's response to insulin, it does **not directly stimulate insulin secretion** from the beta cells.

Q: What is a potential risk associated with the use of thiazolidinediones in the treatment of type 2 diabetes?

Heart failure. ***Heart failure*** - Thiazolidinediones (TZDs), such as **pioglitazone** and **rosiglitazone**, can cause **fluid retention** and **volume expansion**, which may precipitate or worsen congestive heart failure. - This risk is higher in patients with pre-existing cardiac conditions and is a significant concern for these drugs. *Pulmonary fibrosis* - **Pulmonary fibrosis** is not a known or common adverse effect associated with thiazolidinedione use. - This condition is typically linked to certain other medications (e.g., **amiodarone**, **methotrexate**) or systemic diseases. *Myocarditis* - **Myocarditis**, inflammation of the heart muscle, is not a recognized side effect of thiazolidinediones. - Myocarditis is more commonly caused by viral infections, autoimmune diseases, or hypersensitivity reactions to certain drugs, but not TZDs. *Renal dysfunction* - While TZDs can cause fluid retention, they do not directly cause **renal dysfunction** or damage the kidneys. - In fact, some studies suggest they may have renoprotective effects due to reduced proteinuria, although fluid balance needs careful monitoring in patients with impaired renal function.

Q: Which of the following antidiabetic drugs (other than insulin) is indicated as adjunct therapy for the management of both type I and type II diabetes mellitus?

Pramlintide. Pramlintide - Pramlintide is an amylin analog indicated as an adjunct therapy to insulin for both type 1 and type 2 diabetes, helping to regulate post-prandial glucose. - It slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety, leading to reduced insulin requirements and improved glycemic control. Sulphonylureas - Sulphonylureas primarily stimulate insulin secretion from pancreatic beta cells, making them effective only in Type 2 diabetes where some beta-cell function is preserved [2]. - They are not indicated for Type 1 diabetes because these patients have absolute insulin deficiency due to beta cell destruction. Metformin - Metformin is a biguanide that primarily reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues. - It is a first-line treatment for Type 2 diabetes but is generally not used for Type 1 diabetes as it does not address the fundamental lack of insulin. Acarbose - Acarbose is an alpha-glucosidase inhibitor that works by delaying carbohydrate absorption from the gastrointestinal tract, thus reducing postprandial glucose spikes [1]. - While it can be used in Type 2 diabetes to manage postprandial hyperglycemia, it is not typically indicated as an adjunct for Type 1 diabetes alongside insulin [3].

Q: Which of the following medications is relevant in the management of prostatic carcinoma?

Finasteride. ***Finasteride*** - **Finasteride** is a **5α-reductase inhibitor** that blocks the conversion of testosterone to dihydrotestosterone (DHT), which is crucial for prostate growth and development. - It is used in the **chemoprevention of prostatic carcinoma** in high-risk individuals, as demonstrated by the **Prostate Cancer Prevention Trial (PCPT)**, which showed a **25% reduction in prostate cancer risk**. - While finasteride is primarily used for **benign prostatic hyperplasia (BPH)** and **androgenetic alopecia**, its role in reducing prostate cancer risk makes it relevant in prostatic carcinoma management. - It is the only medication among the options with established relevance to prostate cancer. *Danazol* - **Danazol** is an attenuated androgen used primarily for **endometriosis**, **fibrocystic breast disease**, and **hereditary angioedema**. - It suppresses the pituitary-ovarian axis and has **no role in prostatic carcinoma management**. *Clomiphene* - **Clomiphene** is a selective estrogen receptor modulator (SERM) used to induce **ovulation in women** with infertility. - It stimulates gonadotropin release and is **not applicable to prostatic carcinoma** treatment or management. *None of the options* - This is incorrect because **finasteride has an established role** in prostate cancer chemoprevention and is relevant in the broader management of prostatic conditions including carcinoma risk reduction.

Q: Which drug is commonly administered via subdermal implant?

Progestin. ***Progestin*** - **Progestins** (synthetic progestogens like **etonogestrel**) are commonly administered via subdermal implant (e.g., **Nexplanon**, Implanon) for **long-acting reversible contraception (LARC)**. - This method provides a continuous, low dose of hormone, offering effective birth control for **3 years**. - The implant is a small, flexible rod inserted subdermally in the upper arm. *Nicotine* - **Nicotine** is typically administered via **transdermal patches**, gum, inhalers, or nasal sprays for **smoking cessation**, not subdermal implants. - While it's delivered transdermally, the mechanism is through a patch placed on the skin surface, not an implant beneath it. *Fentanyl* - **Fentanyl** is a potent opioid primarily delivered via **transdermal patches** for chronic pain management, or intravenously for acute pain. - It is not administered via a subdermal implant; patches provide continuous release through skin absorption. *GTN* - **Glyceryl trinitrate (GTN)**, or nitroglycerin, is commonly administered as **sublingual tablets** or **transdermal patches** for angina. - It has a very short half-life and is not suitable for a slow-release subdermal implant due to its rapid vasodilatory effects.

Q: Which of the following is not a definite use for Prostaglandin E2 (PGE2)?

Keeps patency of PDA. ***Keeps patency of PDA*** - **Prostaglandin E1 (PGE1)**, not PGE2, is used to maintain the patency of the **ductus arteriosus** in neonates with certain congenital heart defects. - PGE1 causes **vascular smooth muscle relaxation**, preventing closure of the ductus arteriosus. *Contraception* - **PGE2 analogs** are used in various forms of contraception, including emergency contraception and for cervical ripening before elective abortion. - They act by inducing **uterine contractions** and can interfere with implantation or facilitate expulsion of a fertilized egg. *Induces labour* - **PGE2 (dinoprostone)** is commonly used clinically to induce labor by promoting **cervical ripening** and stimulating **uterine contractions**. - It is administered as a vaginal gel or insert to prepare the cervix for delivery. *Therapeutic abortion* - **PGE2 analogs** are used to induce therapeutic abortion, particularly in the second trimester, by causing powerful **uterine contractions** that lead to the expulsion of the fetus. - They are often used in combination with other agents to enhance their efficacy.

Q: Which of the following is a selective progesterone receptor modulator?

Ulipristal. ***Ulipristal*** - **Ulipristal acetate** is a **selective progesterone receptor modulator (SPRM)** that acts as a progesterone receptor agonist/antagonist. - It is primarily used for **emergency contraception** and for the pre-operative treatment of **uterine fibroids**. *Onapristone* - **Onapristone** is an **antiprogestin** and a **progesterone receptor antagonist**, not a selective modulator. - It has been primarily investigated for its potential role in **breast cancer** treatment but is not approved for general clinical use. *Nomegestrol* - **Nomegestrol** is a **synthetic progestin** used in hormonal contraception. - It functions as a **progesterone receptor agonist** and does not exhibit selective modulation properties. *Toremifene* - **Toremifene** is a **selective estrogen receptor modulator (SERM)**, not a progesterone receptor modulator. - It is used in the treatment of **estrogen receptor-positive metastatic breast cancer** in postmenopausal women.

Q: Desmopressin is preferred over vasopressin because it:

Is more potent and has little vasoconstrictor activity. **Is more potent and has little vasoconstrictor activity** - **Desmopressin** is a synthetic analog of **vasopressin** (ADH) that is modified to have much higher selectivity for **V2 receptors** in the renal collecting ducts, leading to potent **antidiuretic effects** [1], [3]. - This selective action results in significantly **reduced vasoconstrictor activity** (mediated by V1 receptors) compared to natural vasopressin, making it safer for clinical use to manage water balance without significant cardiovascular side effects [1], [3]. *Is more potent than vasopressin* - While desmopressin is indeed more potent in its **antidiuretic effect** due to increased affinity for **V2 receptors**, this option alone doesn't specify the critical advantage of *reduced vasoconstrictor activity* [3]. - Its superior potency alone doesn't fully explain its preference over vasopressin, as the **side-effect profile** is a major consideration. *Has little vasoconstrictor activity* - This statement is true and highlights a key advantage of desmopressin, but it omits the fact that **desmopressin is also more potent** in its desired antidiuretic effect compared to natural vasopressin [1]. - Both the **potency** and **reduced vasoconstrictor activity** contribute to its superior clinical profile [3]. *Is more selective for V2 receptors than vasopressin* - **Desmopressin's increased selectivity** for **V2 receptors** is the mechanistic basis for its preferred properties, leading to both greater antidiuretic potency and reduced vasoconstriction [1], [4]. - However, the option "Is more potent and has little vasoconstrictor activity" describes the *clinical consequences* of this selectivity, which are the direct reasons for its preferred use [2].

Q: Finasteride is classified as a:

5-alpha reductase inhibitor. ### ***5-alpha reductase inhibitor*** - **Finasteride** specifically inhibits the enzyme **5-alpha reductase**, preventing the conversion of **testosterone** to **dihydrotestosterone (DHT)** [2], [4]. - This reduction in DHT is clinically useful for treating conditions like **benign prostatic hyperplasia (BPH)** and **androgenetic alopecia** [4]. ### *Phosphodiesterase inhibitor* - **Phosphodiesterase inhibitors** (e.g., sildenafil) typically work by increasing levels of **cyclic GMP**, leading to **vasodilation** and are used for **erectile dysfunction** [3]. - Their mechanism of action is distinct from finasteride's effect on **hormone metabolism**. ### *Alpha-1 blocker* - **Alpha-1 blockers** (e.g., tamsulosin) primarily relax **smooth muscle** in the prostate and bladder neck, improving **urine flow** in BPH [3], [5]. - They act on **adrenergic receptors** and do not affect **hormone synthesis** or **metabolism** [3]. ### *Androgen receptor antagonist* - **Androgen receptor antagonists** (e.g., flutamide) directly block the binding of **androgens** (like testosterone and DHT) to their receptors [1], [4]. - While they also affect androgen action, their mechanism is different from finasteride's **enzyme inhibition** [4].

Question 1

What conditions is Metformin primarily used to treat?

Accepted Answer

Both Type 2 Diabetes and Polycystic Ovary Syndrome (PCOS)

Answer

Only Type 2 Diabetes

Answer

Only Polycystic Ovary Syndrome (PCOS)

Answer

Pregnancy Induced Hypertension

Question 2

Which medication increases insulin secretion from beta cells?

Accepted Answer

Repaglinide

Answer

Metformin

Answer

Pioglitazone

Answer

Pramlintide

Question 3

What is a potential risk associated with the use of thiazolidinediones in the treatment of type 2 diabetes?

Accepted Answer

Heart failure

Answer

Pulmonary fibrosis

Answer

Myocarditis

Answer

Renal dysfunction

Question 4

Which of the following antidiabetic drugs (other than insulin) is indicated as adjunct therapy for the management of both type I and type II diabetes mellitus?

Accepted Answer

Pramlintide

Answer

Sulphonylureas

Answer

Metformin

Answer

Acarbose

Question 5

Which of the following medications is relevant in the management of prostatic carcinoma?

Accepted Answer

Finasteride

Answer

Clomiphene

Answer

None of the options

Answer

Danazol

Question 6

Which drug is commonly administered via subdermal implant?

Accepted Answer

Progestin

Answer

Nicotine

Answer

Fentanyl

Answer

GTN

Question 7

Which of the following is not a definite use for Prostaglandin E2 (PGE2)?

Accepted Answer

Keeps patency of PDA

Answer

Induces labour

Answer

Contraception

Answer

Therapeutic abortion

Question 8

Which of the following is a selective progesterone receptor modulator?

Accepted Answer

Ulipristal

Answer

Onapristone

Answer

Nomegestrol

Answer

Toremifene

Question 9

Desmopressin is preferred over vasopressin because it:

Accepted Answer

Is more potent and has little vasoconstrictor activity

Answer

Is more potent than vasopressin

Answer

Has little vasoconstrictor activity

Answer

Is more selective for V2 receptors than vasopressin

Question 10

Finasteride is classified as a:

Accepted Answer

5-alpha reductase inhibitor

Answer

Phosphodiesterase inhibitor

Answer

Alpha-1 blocker

Answer

Androgen receptor antagonist

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?